Within six months of treatment, 17 immunized babies developed invasive pneumococcal disease, a rate of 14.2 per 100,000. The FDA approved a second antibody injection, clesrovimab, in 2025, and the maternal RSV vaccine Abrysvo is given between 32 and 36 weeks of pregnancy. Prevnar remains the approved and recommended protection against pneumococcal disease in children. Eligibility depends on age, birth timing relative to RSV season, and whether the mother received the maternal RSV vaccine. What is invasive pneumococcal disease?